Robert Dubois, MD, PhD, shares findings from their recently published study in The American Journal of Managed Care, which showed that patients do not know they are being treated on predetermined pathways.
“How aware are patients about their clinician using or treating them on a clinical pathway? Is there awareness among the patient population of any financial incentives that might be involved in the process?” Surabhi Dangi-Garimella, PhD, asked the panelists.
Robert Dubois, MD, PhD, believes that there is minimal awareness among patients—as they discovered from a recent study that was published in The American Journal of Managed Care—and that this is both surprising and disconcerting.
The least transparent thing for patients is the financial incentives attached to pathway compliance. “Certainly, in the world of fee-for-service medicine there were concerns that patients may be receiving more care than they absolutely need, but as we move to a world where payments are going to be fixed, now there’s a concern that there could be some sort of underuse,” added Dr Dubois.
As such, Dr Dubois believes that moving forward there should be 2 things that are made clear to patients. First, that there are pathways in use and that there are ways around these pathways if needed. And second, there are financial incentives to adherence and that if a doctor falls below a certain percentage there may be financial consequences.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More